Predicting the Risk of Radiation Pneumonitis and Pulmonary Function Changes after Breast Cancer Radiotherapy.

3-D Conformal Radiotherapy Breast Cancer Lung Radiation Pneumonitis Spirometry

Journal

Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 10 12 2018
accepted: 29 12 2018
entrez: 30 8 2021
pubmed: 31 8 2021
medline: 31 8 2021
Statut: epublish

Résumé

Radiotherapy plays an important role in the treatment of breast cancer. In the process of radiotherapy, the underling lung tissue receives higher doses from treatment field, which led to incidence of radiation pneumonitis. The present study aims to evaluate the predictive factors of radiation pneumonitis and related changes in pulmonary function after 3D-conformal radiotherapy of breast cancer. In prospective basis study, thirty-two patients with breast cancer who received radiotherapy after surgery, were followed up to 6 months. Respiratory symptoms, lung radiologic changes and pulmonary function were evaluated. Radiation pneumonitis (RP) was graded according to common terminology criteria for adverse events (CTCAE) version 3.0. Dose-volume parameters, which included percentage of lung volume receiving dose of d Gy (V Eight patients developed RP. Among the dose-volume parameters, V Pulmonary function parameters, especially FEV1, significantly decreased at 3 and 6 months after radiotherapy. Since most patients with breast cancer who developed RP did not show obvious clinical symptoms, so spirometry test is beneficial to identify patients with risk of radiation pneumonitis.

Sections du résumé

BACKGROUND BACKGROUND
Radiotherapy plays an important role in the treatment of breast cancer. In the process of radiotherapy, the underling lung tissue receives higher doses from treatment field, which led to incidence of radiation pneumonitis.
OBJECTIVE OBJECTIVE
The present study aims to evaluate the predictive factors of radiation pneumonitis and related changes in pulmonary function after 3D-conformal radiotherapy of breast cancer.
MATERIAL AND METHODS METHODS
In prospective basis study, thirty-two patients with breast cancer who received radiotherapy after surgery, were followed up to 6 months. Respiratory symptoms, lung radiologic changes and pulmonary function were evaluated. Radiation pneumonitis (RP) was graded according to common terminology criteria for adverse events (CTCAE) version 3.0. Dose-volume parameters, which included percentage of lung volume receiving dose of d Gy (V
RESULTS RESULTS
Eight patients developed RP. Among the dose-volume parameters, V
CONCLUSION CONCLUSIONS
Pulmonary function parameters, especially FEV1, significantly decreased at 3 and 6 months after radiotherapy. Since most patients with breast cancer who developed RP did not show obvious clinical symptoms, so spirometry test is beneficial to identify patients with risk of radiation pneumonitis.

Identifiants

pubmed: 34458193
doi: 10.31661/jbpe.v0i0.1079
pii: JBPE-11-4
pmc: PMC8385223
doi:

Types de publication

Journal Article

Langues

eng

Pagination

459-464

Informations de copyright

Copyright: © Journal of Biomedical Physics and Engineering.

Références

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):701-7
pubmed: 21398052
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Oncotarget. 2017 May 16;8(20):33855-33863
pubmed: 27806340
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407
pubmed: 16997503
In Vivo. 2009 Sep-Oct;23(5):867-71
pubmed: 19779125
J Clin Oncol. 1995 Oct;13(10):2606-12
pubmed: 7595714
Breast J. 2007 Jul-Aug;13(4):383-91
pubmed: 17593043
Radiother Oncol. 2009 Jun;91(3):427-32
pubmed: 18937989
Radiat Oncol. 2010 May 12;5:35
pubmed: 20462424
PLoS One. 2015 Jul 06;10(7):e0131736
pubmed: 26147496
J Clin Oncol. 2004 Dec 1;22(23):4691-9
pubmed: 15570071
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):5-24
pubmed: 15963660
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Radiat Oncol. 2014 Jul 30;9:172
pubmed: 25074618
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6
pubmed: 20171521
Breast Cancer Res Treat. 2001 Aug;68(3):199-210
pubmed: 11727957
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):110-5
pubmed: 12504042
J Thorac Oncol. 2007 Sep;2(9):864-74
pubmed: 17805067
Radiat Oncol J. 2013 Mar;31(1):34-40
pubmed: 23620867

Auteurs

Parinaz Mehnati (P)

PhD, Immunology research center, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Maryam Ghorbanipoor (M)

MSc, Department of Medical Physics, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Mohammadzadeh (M)

MD, Department of Radiology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Behnam Nasiri Motlagh (B)

MD, Department of Radiology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Asghar Mesbahi (A)

PhD, Medical Radiation Sciences Research team, Department of Medical Physics, School of Medicine, Tabriz, Iran.

Classifications MeSH